Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 2/2007

Open Access 01-04-2007 | Research

Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review

Authors: Dinna N Cruz, Mark A Perazella, Rinaldo Bellomo, Massimo de Cal, Natalia Polanco, Valentina Corradi, Paolo Lentini, Federico Nalesso, Takuya Ueno, V Marco Ranieri, Claudio Ronco

Published in: Critical Care | Issue 2/2007

Login to get access

Abstract

Introduction

Severe sepsis and septic shock are common problems in the intensive care unit and carry a high mortality. Endotoxin, one of the principal components on the outer membrane of gram-negative bacteria, is considered important to their pathogenesis. Polymyxin B bound and immobilized to polystyrene fibers (PMX-F) is a medical device that aims to remove circulating endotoxin by adsorption, theoretically preventing the progression of the biological cascade of sepsis. We performed a systematic review to describe the effect in septic patients of direct hemoperfusion with PMX-F on outcomes of blood pressure, use of vasoactive drugs, oxygenation, and mortality reported in published studies.

Methods

We searched PubMed, the Cochrane Collaboration Database, and bibliographies of retrieved articles and consulted with experts to identify relevant studies. Prospective and retrospective observational studies, pre- and post-intervention design, and randomized controlled trials were included. Three authors reviewed all citations. We identified a total of 28 publications – 9 randomized controlled trials, 7 non-randomized parallel studies, and 12 pre-post design studies – that reported at least one of the specified outcome measures (pooled sample size, 1,425 patients: 978 PMX-F and 447 conventional medical therapy).

Results

Overall, mean arterial pressure (MAP) increased by 19 mm Hg (95% confidence interval [CI], 15 to 22 mm Hg; p < 0.001), representing a 26% mean increase in MAP (range, 14% to 42%), whereas dopamine/dobutamine dose decreased by 1.8 μg/kg per minute (95% CI, 0.4 to 3.3 μg/kg per minute; p = 0.01) after PMX-F. There was significant intertrial heterogeneity for these outcomes (p < 0.001), which became non-significant when analysis was stratified for baseline MAP. The mean arterial partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio increased by 32 units (95% CI, 23 to 41 units; p < 0.001). PMX-F therapy was associated with significantly lower mortality risk (risk ratio, 0.53; 95% CI, 0.43 to 0.65). The trials assessed had suboptimal method quality.

Conclusion

Based on this critical review of the published literature, direct hemoperfusion with PMX-F appears to have favorable effects on MAP, dopamine use, PaO2/FiO2 ratio, and mortality. However, publication bias and lack of blinding need to be considered. These findings support the need for further rigorous study of this therapy.
Appendix
Available only for authorised users
Literature
1.
Angus D, Wax R: Epidemiology of sepsis: an update. Crit Care Med 2001,29(7 Suppl):S109-116. 10.1097/00003246-200107001-00035CrossRefPubMed
2.
Marshall J, Foster D, Vincent J, Cook D, Cohen J, Dellinger R, Opal S, Abraham E, Brett S, Smith T, et al.: Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 2004, 190: 527-534. 10.1086/422254CrossRefPubMed
3.
Hattar K, Grandel U, Moeller A, Fink L, Iglhaut J, Hartung T, Morath S, Seeger W, Grimminger F, Sibelius U: Lipoteichoic acid (LTA) from Staphylococcus aureus stimulates human neutrophil cytokine release by a CD 14-dependent, Toll-like-receptor-independent mechanism: autocrine role of tumor necrosis factor-alpha in mediating LTA-induced interleukin-8 generation. Crit Care Med 2006, 34: 835-841.PubMed
4.
Manocha S, Feinstein D, Kumar A, Kumar A: Novel therapies for sepsis: antiendotoxin therapies. Expert Opin Investig Drugs 2002, 11: 1795-1812. 10.1517/13543784.11.12.1795CrossRefPubMed
5.
Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NN, et al.: Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991, 324: 429-436.CrossRefPubMed
6.
McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR: Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 1994, 121: 1-5.CrossRefPubMed
7.
Shoji H: Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial 2003, 7: 108-114. 10.1046/j.1526-0968.2003.00005.xCrossRefPubMed
8.
Nakamura T, Ushiyama C, Suzuki Y, Inoue T, Shoji H, Shimada N, Koide H: Combination therapy with polymyxin B-immobilized fibre haemoperfusion and teicoplanin for sepsis due to methicillin-resistant Staphylococcus aureus. J Hosp Infect 2003, 53: 58-63. 10.1053/jhin.2002.1332CrossRefPubMed
9.
Nakamura T, Kawagoe Y, Matsuda T, Ueda Y, Koide H: Effects of polymyxin B-immobilized fiber on urinary N-acetyl-B-glucosaminidase in patients with severe sepsis. ASAIO Journal 2004, 50: 563-567. 10.1097/01.MAT.0000142875.62592.3ACrossRefPubMed
10.
Nakamura T, Ebihara I, Shoji H, Ushiyama C, Suzuki S, Koide H: Treatment with polymyxin B-immobilized fiber reduces platelet activation in septic shock patients: decrease in plasma levels of soluble P-selectin, platelet factor-4 and beta-thromboglobulin. Inflamm Res 1999, 48: 171-175. 10.1007/s000110050442CrossRefPubMed
11.
Nakamura T, Ushiyama C, Suzuki Y, Shoji H, Shimada N, Koide H: Hemoperfusion with polymyxin-B immobilized fiber for urinary albumin excretion in septic patients with trauma. ASAIO Journal 2002, 48: 244-248. 10.1097/00002480-200205000-00008CrossRefPubMed
12.
Nakamura T, Ushiyama C, Suzuki Y, Osada S, Inoue T, Shoji H, Hara M, Shimada N, Koide H: Hemoperfusion with polymyxin-B immobilized fiber in septic patients with methicillin-resistant Staphylococcus aureus-associated glomerulonephritis. Nephron Clin Pract 2003, 94: c33-c39. 10.1159/000071279CrossRefPubMed
13.
Nakamura T, Kawagoe Y, Matsuda T, Koide H: Effect of polymyxin B-immobilized fiber on bone resorption in patients with sepsis. Intensive Care Med 2004, 30: 1838-1841. 10.1007/s00134-004-2357-7CrossRefPubMed
14.
Nemoto H, Nakamoto H, Okada H, Sugahara S, Moriwaki K, Arai M, Kanno Y, Suzuki H: Newly developed polymyxin B-immobilized fibers improve the survival of patients with sepsis. Blood Purif 2001, 19: 361-369. 10.1159/000046966CrossRefPubMed
15.
Suzuki H, Nemoto H, Nakamoto H, Okada H, Sugahara S, Kanno Y, Moriwaki K: Continuous hemodiafiltration with polymyxin B-immobilized fiber is effective in patients with sepsis syndrome and acute renal failure. Ther Apher 2002, 6: 234-240. 10.1046/j.1526-0968.2002.00416.xCrossRefPubMed
16.
Nakamura T, Ebihara I, Shimada N, Suzuki S, Ushiyama C, Shoji H, Koide H: Effects of hemoperfusion with polymyxin B-immobilized fibre on serum neopterin and soluble interleukin-2 receptor concentrations in patients with septic shock. J Infect 1998, 37: 241-247. 10.1016/S0163-4453(98)91952-1CrossRefPubMed
17.
Nakamura T, Ebihara I, Shimada N, Koide H: Changes in plasma erythropoietin and interleukin-6 concentrations in patients with septic shock after hemoperfusion and polymyxin B-immobilized fiber. Intensive Care Med 1998, 24: 1272-1276. 10.1007/s001340050761CrossRefPubMed
18.
Nakamura T, Kawagoe Y, Matsuda T, Shoji H, Ueda Y, Tamura N, Ebihara I, Koide H: Effect of polymyxin B-immobilized fiber on blood metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in acute respiratory distress syndrome patients. Blood Purif 2004, 22: 256-260. 10.1159/000078494CrossRefPubMed
19.
Nakamura T, Kawagoe Y, Sukuzi T, Shoji H, Ueda Y, Kobayashi N, Koide H: Changes in plasma interleukin-18 by direct hemoperfusion with polymyxin B-immobilized fiber in patients with septic shock. Blood Purif 2005, 23: 417-420. 10.1159/000088016CrossRefPubMed
20.
Shimada N, Nakamura T, Takayashi Y, Tanaka A, Shoji H, Sekizuka K, Ebihara I, Koide H: Effects of polymyxin B-immobilized fiber on serum phosphate concentrations in patients with sepsis. Nephron 2000, 86: 359-360. 10.1159/000045800CrossRefPubMed
21.
Tani T, Hanasawa K, Endo Y, Yoshioka T, Kodama M, Kaneko M, Uchiyama Y, Akizawa T, Takahashi K, Sugai T: Therapeutic apheresis for septic patients with organ dysfunction: hemoperfusion using a polymyxin-B immobilized column. Artif Organs 1998, 22: 1038-1044. 10.1046/j.1525-1594.1998.06086.xCrossRefPubMed
22.
Tojimbara T, Sato S, Nakajima I, Fuchinoue S, Akiba T, Teraoka S: Polymyxin B-immobilized fiber hemoperfusion after emergency surgery in patients with chronic renal failure. Ther Apher Dial 2004, 8: 286-292. 10.1111/j.1526-0968.2004.00166.xCrossRefPubMed
23.
Ueno T, Sugino M, Nemoto H, Shoji H, Kakita A, Watanabe M: Effect over time of endotoxin adsorption therapy in sepsis. Ther Apher Dial 2005, 9: 128-136. 10.1111/j.1774-9987.2005.00230.xCrossRefPubMed
24.
Uriu K, Osajima A, Kamochi M, Watanabe H, Aibara K, Kaizu K: Endotoxin removal by direct hemoperfusion with an adsorbent column using polymyxin B-immobilized fiber ameliorates systemic circulatory disturbance in patients with septic shock. Am J Kidney Dis 2002, 39: 937-947. 10.1053/ajkd.2002.32767CrossRefPubMed
25.
Ronco C: The place of early haemoperfusion with polymyxin B-immobilized fibre column in the treatment of sepsis. Crit Care 2005, 9: 631-633. 10.1186/cc3890PubMedCentralCrossRefPubMed
26.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996, 17: 1-12. 10.1016/0197-2456(95)00134-4CrossRefPubMed
27.
Follmann D, Elliott P, Suh I, Cutler J: Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992, 45: 769-773. 10.1016/0895-4356(92)90054-QCrossRefPubMed
28.
Vincent J, Laterre P, Cohen J, Burchardi H, Bruining H, Lerma F, Wittebole X, de Backer D, Brett S, Marzo D, et al.: A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005, 23: 400-405. 10.1097/01.shk.0000159930.87737.8aCrossRefPubMed
29.
Nakamura T, Matsuda T, Suzuki Y, Shoji H, Koide H: Polymyxin B-immobilized fiber in patients with sepsis. Dialysis Transplant 2003, 32: 602-607.
30.
Ono S, Tsujinomoto H, Matsumoto A, Ikuta S, Kinoshita M, Michizuki H: Modulation of human leukocyte antigen-DR on monocytes and CD16 on granulocytes in patients with polymyxin B-immobilized fiber. Am J Surg 2004, 188: 150-156. 10.1016/j.amjsurg.2003.12.067CrossRefPubMed
31.
Tsugawa K, Koyanagi N, Hashizume M, Wada H, Ayukawa K, Akahoshi K, Tomikawa M, Sugimachi K: Results of endotoxin absorption after a subtotal resection of the small intestine and a right hemicolectomy for severe superior mesenteric ischemia. Hepatogastroenterology 2002, 49: 1303-1306.PubMed
32.
Tsujimoto H, Ono S, Hiraki S, Majima T, Kawarabayashi N, Sugasawa H, Kinoshita M, Hiraide H, Mochizuki H: Hemoperfusion with polymyxin B-immobilized fibers reduced the number of CD16 + CD14 + monocytes in patients with septic shock. J Endotoxin Res 2004, 10: 229-237. 10.1179/096805104225005814PubMed
33.
Tsushima K, Kubo K, Koizumi T, Yamamoto H, Fujimoto K, Hora K, Kan-nou Y: Direct hemoperfusion using a polymyxin B immobilized column improves acute respiratory. J Clin Apheresis 2002, 17: 97-102. 10.1002/jca.10019CrossRefPubMed
34.
Ikeda T, Ikeda K, Nagura M, Taniuchi H, Matsushita M, Kiuchi S, Kuroki Y, Suzuki K, Matsuno N: Clinical evaluation of PMX-DHP for hypercytokinemia caused by septic multiple organ failure. Ther Apher Dial 2004, 8: 293-298. 10.1111/j.1526-0968.2004.00167.xCrossRefPubMed
35.
Kushi H, Miki T, Okamoto K, Nakahara J, Saito T, Tanjoh K: Early haemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation. Critical Care 2005, 9: R653-R661. 10.1186/cc3815PubMedCentralCrossRefPubMed
36.
Tani T, Hanasawa K, Kodama M, Imaizumi H, Yonekawa M, Saito M, Ikeda T, Yagi Y, Takayama K, Amano I, et al.: Correlation between plasma endotoxin, plasma cytokines, and plasminogen activator inhibitor-1 in septic patients. World J Surg 2001, 25: 660-8. 10.1007/s002680020028CrossRefPubMed
37.
Kojika M, Sato N, Yaegashi Y, Suzuki Y, Suzuki K, Nakae H, Sigeatu Endo S: Endotoxin adsorption therapy for septic shock using polymyxin B-immobilized fibers (PMX): evaluation by high-sensitivity endotoxin assay and measurement of the cytokine production capacity. Ther Apher Dial 2006, 10: 12-18. 10.1111/j.1744-9987.2006.00340.xCrossRefPubMed
38.
Casella G, Monti G, Terzi V, Pulici M, Ravizza A, Vesconi S: Non-conventional therapies in refractory septic shock: clinical experience with Polymyxin B. [in Italian]. Minerva Anestesiol 2006,72(Suppl 1):63-67.
39.
Aoki H, Kodama M, Tani T, Hanasawa K: Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B immobilized fiber. Am J Surg 1994, 167: 412-417. 10.1016/0002-9610(94)90126-0CrossRefPubMed
40.
Bone R, Balk R, Cerra F, Dellinger R, Fein A, Knaus W, Schein R, Sibbald J: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101: 1644-1655.CrossRefPubMed
41.
Kodama M, Tani T, Hanasawa K, Hirata K, Hirasawa H, Oda S, Otsuka T, Yamamoto Y, Kanesaka S, Takahashi Y, et al.: Treatment of sepsis by plasma endotoxin removal: Hemoperfusion using a polymyxin-B immobilized column. J Endotoxin Res 1997, 4: 293-300.
42.
Uriu K, Osajima A, Kamochi M, Watanabe H, Aibara K, Kaizu K: The severity of hyperdynamic circulation may predict the effects of direct hemoperfusion with the absorbent column using polymyxin B-immobilized fiber in patients with gram-negative septic shock. Ther Apher 2001, 5: 25-30. 10.1046/j.1526-0968.2001.005001025.xCrossRefPubMed
43.
Kushi H, Nakahara J, Miki T, Okamoto K, Saito T, Tanjo K: Hemoperfusion with an immobilized polymyxin B fiber column inhibits activation of vascular endothelial cells. Ther Apher Dial 2005, 9: 303-307. 10.1111/j.1744-9987.2005.00286.xCrossRefPubMed
44.
Kushi H, Miki T, Nakahara J, Okamoto K, Saito T, Tanjoh K: Hemoperfusion with an immobilized polymyxin B column reduces the blood level of neutrophil elastase. Blood Purif 2006, 24: 212-217. 10.1159/000090593CrossRefPubMed
45.
Kohro S, Imaizumi H, Yamakage M, Masuda Y, Namiki A, Asai Y, Maruyama I: Anandamide absorption by direct hemoperfusion with polymyxin B-immobilized fiber improves the prognosis and organ failure assessment score in patients with sepsis. J Anesth 2006, 20: 11-16. 10.1007/s00540-005-0366-5CrossRefPubMed
46.
Annane D, Sébille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, et al.: Effect of a treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002, 288: 862-971. 10.1001/jama.288.7.862CrossRefPubMed
47.
Amato MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-Filho G, Kairalla RA, Deheinzelin D, Munoz C, Oliveira R, et al.: Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998, 338: 347-354. 10.1056/NEJM199802053380602CrossRefPubMed
48.
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, Early Goal-Directed Therapy Collaborative Group: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345: 1368-1377. 10.1056/NEJMoa010307CrossRefPubMed
49.
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344: 699-709. 10.1056/NEJM200103083441001CrossRefPubMed
Metadata
Title
Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review
Authors
Dinna N Cruz
Mark A Perazella
Rinaldo Bellomo
Massimo de Cal
Natalia Polanco
Valentina Corradi
Paolo Lentini
Federico Nalesso
Takuya Ueno
V Marco Ranieri
Claudio Ronco
Publication date
01-04-2007
Publisher
BioMed Central
Published in
Critical Care / Issue 2/2007
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc5780

Other articles of this Issue 2/2007

Critical Care 2/2007 Go to the issue

Review

Bench-to-bedside review: When is dead really dead – on the legitimacy of using neurologic criteria to determine death

Commentary

Do-not-resuscitate orders, unintended consequences, and the ripple effect

Research

Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis

Book report

Fawcett JAD: Hemodynamic Monitoring Made Easy, 1st edition. China: Elsevier

Research

Case mix, outcome and activity for patients admitted to intensive care units requiring chronic renal dialysis: a secondary analysis of the ICNARC Case Mix Programme Database

Book report

DeVita MA, Hillman K, Bellomo R (Eds): Medical Emergency Teams: Implementation and Outcome Measurement,1st edition. New York: Springer